Ditiocarb Sodium for Immune Function Restoration in AIDS and ARC Patients

This study focuses on a drug called ditiocarb sodium, or DTC, and its potential benefits for patients diagnosed with AIDS and AIDS Related Complex (ARC). The main goal is to understand if DTC can help improve the immune system and overall health of these patients. The study also aims to find out if DTC can alleviate symptoms associated with ARC, slow down the progression from ARC to AIDS, or even delay the worsening of AIDS. Ultimately, the researchers hope to discover if DTC can extend the lifespan of individuals living with AIDS. During this treatment study, participants will receive DTC. The effects of DTC on the immune system and overall health will be carefully monitored. Researchers will observe if there are any improvements in ARC symptoms, and if the progression of the disease slows down. They will also track the survival rates of the participants to understand the potential long-term benefits of DTC. It's important to note that every medical study carries potential risks and benefits, which will be thoroughly explained to each participant before they decide to take part in the study.